Personalized Medicine in Oncology in the Developing World: Barriers and Concepts to Improve Status Quo
| Autor: | Michael Gary Martin, Adeoluwa Akeem Adeniji, Soniya Dulal |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Developing world
Oncology Cancer Research medicine.medical_specialty Patient stratification Status quo business.industry Cost effectiveness media_common.quotation_subject Individualized patient profiling Developing country Review Direct cost Personalized medicine Human development (humanity) Variety (cybernetics) Internal medicine Medicine In patient business Barriers Cost-efficacy media_common |
| Zdroj: | World Journal of Oncology |
| ISSN: | 1920-454X 1920-4531 |
| DOI: | 10.14740/wjon1345 |
| Popis: | Personalized medicine (PM) has revolutionized oncology management in high human development indexed countries. By interrogating both disease and host factors through a variety of tools, oncologists have been able to better target an individual's cancer, leading to improved outcomes. But both the tools used to define these variables, such as next generation sequencing, large immunohistochemical and fluorescence in situ hybridization (FISH) panels, and the weapons employed against each target are extremely expensive. The expenses have to be measured as not only the direct cost to the patient but also the cost to the system to develop and deploy the necessary infrastructure to optimally use them. However, the concepts of predictive, timely prevention and PM have demonstrated improvement in patient's satisfaction and cost effectiveness. In this paper we will summarize the relevant barriers and challenges that limit the implementation of PM in the developing world with an emphasis on the challenges in Nigeria and Nepal. World J Oncol. 2021;12(2-3):50-60 doi: https://doi.org/10.14740/wjon1345 |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|